Lycia Therapeutics
400 East Jamie Court,
Suite 200
South San Francisco
CA
94080
United States
Website: https://lyciatx.com/
Email: info@lyciatx.com
7 articles about Lycia Therapeutics
-
Lycia Therapeutics Founder Dr. Carolyn Bertozzi Awarded 2022 Nobel Prize in Chemistry
10/5/2022
Lycia Therapeutics, Inc. announced that founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in Chemistry.
-
Lycia Therapeutics Strengthens Leadership Team with Appointment of Steve Staben, Ph.D. as Chief Scientific Officer
2/28/2022
Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the recent appointment of Steve Staben, Ph.D., as Chief Scientific Officer.
-
Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.
-
Money on the Move: September 8 – 14
9/15/2021
Ramping up after the Labor Day holiday, funds are flowing fast and free into these life science companies. -
Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures
9/9/2021
Lycia Therapeutics, Inc. today announced the completion of an oversubscribed $70 million Series B financing.
-
Lycia will be receiving a $35 million upfront payment from Lilly and is eligible for over $1.6 billion in potential milestone payments.
-
Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders
8/25/2021
Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology.